1. Home
  2. VNDA vs MIN Comparison

VNDA vs MIN Comparison

Compare VNDA & MIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VNDA
  • MIN
  • Stock Information
  • Founded
  • VNDA N/A
  • MIN 1988
  • Country
  • VNDA United States
  • MIN United States
  • Employees
  • VNDA N/A
  • MIN N/A
  • Industry
  • VNDA Biotechnology: Pharmaceutical Preparations
  • MIN Trusts Except Educational Religious and Charitable
  • Sector
  • VNDA Health Care
  • MIN Finance
  • Exchange
  • VNDA Nasdaq
  • MIN Nasdaq
  • Market Cap
  • VNDA 362.6M
  • MIN 301.0M
  • IPO Year
  • VNDA 2006
  • MIN N/A
  • Fundamental
  • Price
  • VNDA $6.30
  • MIN $2.68
  • Analyst Decision
  • VNDA Buy
  • MIN
  • Analyst Count
  • VNDA 1
  • MIN 0
  • Target Price
  • VNDA $11.00
  • MIN N/A
  • AVG Volume (30 Days)
  • VNDA 836.8K
  • MIN 331.0K
  • Earning Date
  • VNDA 07-29-2024
  • MIN 01-01-0001
  • Dividend Yield
  • VNDA N/A
  • MIN 7.31%
  • EPS Growth
  • VNDA N/A
  • MIN N/A
  • EPS
  • VNDA N/A
  • MIN 0.08
  • Revenue
  • VNDA $177,604,000.00
  • MIN N/A
  • Revenue This Year
  • VNDA $2.98
  • MIN N/A
  • Revenue Next Year
  • VNDA $19.49
  • MIN N/A
  • P/E Ratio
  • VNDA N/A
  • MIN $33.38
  • Revenue Growth
  • VNDA N/A
  • MIN N/A
  • 52 Week Low
  • VNDA $3.30
  • MIN $2.52
  • 52 Week High
  • VNDA $6.75
  • MIN $2.88
  • Technical
  • Relative Strength Index (RSI)
  • VNDA 61.57
  • MIN 54.54
  • Support Level
  • VNDA $5.89
  • MIN $2.68
  • Resistance Level
  • VNDA $6.37
  • MIN $2.73
  • Average True Range (ATR)
  • VNDA 0.24
  • MIN 0.02
  • MACD
  • VNDA 0.06
  • MIN -0.00
  • Stochastic Oscillator
  • VNDA 94.35
  • MIN 37.50

About VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.

About MIN MFS Intermediate Income Trust

MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises of different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.

Share on Social Networks: